GlassScriptPhysician profile
Yu-Wei Chen
NPI 1245694801
$8,770.22
in general payments reported to CMS, 2019-2025
14 companies · $5,142 in 2025
The $5,142 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2023: $375 · 2024: $3,001 · 2025: $5,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,500 · Food and Beverage: $2,918 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,500.00 |
| Food and Beverage | $2,917.69 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $4,523.75 | 2024-2025 | |
| Janssen Biotech, INC. | $1,383.16 | 2025 | Erleada |
| Exelixis INC. | $1,066.31 | 2021-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $684.27 | 2023-2025 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $225.03 | 2023-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $186.96 | 2024-2025 | Lynparza |
| Pfizer INC. | $150.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $131.24 | 2021 | |
| Janssen Scientific Affairs, LLC | $129.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.06 | 2025 | |
| Astellas Pharma US INC | $85.70 | 2025 | Xtandi |
| Merck Sharp & Dohme LLC | $34.97 | 2024 | Keytruda, Welireg |
| Caris Mpi, INC. | $28.16 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $24.61 | 2025 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu-Wei Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.